Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 4/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262554 | 0.89 | PTPN1 (0.60) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL1262282 | 0.82 | PTPN2 (0.46) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL1262989 | 0.81 | PTPN1 (0.50) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL27682780 | 0.80 | PTPN2 (0.46) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL23086091 | 0.76 | STS (0.67) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL29286246 | 0.75 | HPGDS (0.48) | PTPN2PTPN1PTPN6STSKMT2A | |
| SCHEMBL1263685 | 0.74 | PTPN1 (0.45) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL4604242 | 0.73 | PIK3CA (0.53) | NPC1RAB9AKMT2A | |
| SCHEMBL4938088 | 0.73 | PIK3CA (0.54) | NPC1RAB9A | |
| SCHEMBL4605845 | 0.73 | PTPN1 (0.50) | PTPN2PTPN1PTPN6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768978-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| CN-101014590-A | 2,4, 6-trisubstituted pyrimidines as Phosphatidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | PTPN2 1922/4885PTPN1 1863/4885PTPN6 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.